David Shum is the Group Leader for Screening Discovery Platform at Institut Pasteur Korea which focuses on early drug discovery, high-content, and high-throughput screening. Since graduating with a MSc in Biology from New York University in 2002 and more recently a MBA from University of Illinois – Urbana Champaign, he has worked for nearly 20 years exploring phenotypic-based approaches to unravel disease mechanisms whereby refining the drug discovery pipeline. Early in his career, David was part of a multi-institutional project (GE Healthcare, Amersham Biosciences, and Memorial Sloan Kettering Cancer Center) to develop and validate one of first high-throughput confocal microscopes for use in screening. Soon afterwards, he applied these techniques at the High-Throughput Screening Core Facility in MSKCC on an industrial scale to screen small molecules and functional genomic tools to understand essential mechanisms in oncology. This hospital research setting allowed for improved translation from bench to clinic with development of phenotypic assay models around patient derived tumor samples, co-cultures, iPSCs, and 3D organoids. In the current position at IPK, David and his team are focused on infectious diseases and building advanced phenotypic assay models along viral, parasitic, and microbial pathogens. The work is centered on combining multidisciplinary approaches in biology, chemistry, informatics including Ai towards providing an essential pipeline to prepare and respond to pandemics.